Press release content from Business Wire. The AP news staff was not involved in its creation.
DiaMedica Therapeutics Hosting Key Opinion Leader Webinar on DM199 for Treatment of Acute Ischemic Stroke
March 9, 2021 GMT
MINNEAPOLIS (BUSINESS WIRE) Mar 9, 2021
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel treatments for neurological and kidney diseases, today announced that it will host a key opinion leader (KOL) webinar on DM199, the Company’s lead asset for the treatment of Acute Ischemic Stroke (AIS), on Friday, March 19, 2021 at 12:00pm Eastern Time.
The webinar will feature presentations by KOLs Scott Kasner, M.D., University of Pennsylvania, and Paolo Madeddu, M.D., University of Bristol, who will discuss the current treatment landscape and unmet medical need in treating patients with AIS and the rationale for the treatment of stroke and stroke recurrence with DM199. Drs. Kasner and Madeddu will be available to answ